Exchange: NASDAQ·Updated 07:56 PM EST
EDIT logo

EDIT Editas Medicine Inc

$1.64
$0.07
(4.09%)
Today
Closed $1.64
$0.02
(1.22%)
After Hours
Reported EarningsNov 9
Mkt Cap$253.12M
Vol2.68M

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.
37

Bearish Sentiment

How do you feel about EDIT?

Ftavvv
$EDIT • Nov 8: AHA Presentation (EDIT-401 Preclinical Data) • Nov 9: Q3 Earnings Release (Before Market Opens) • Nov 10: Guggenheim Conference (Fireside Chat & Analyst Q&A) • Nov 11: First-in-Human Dosing 11.11 means four 1s, which stands for EDIT-401
7
Ftavvv
$EDIT FDA UNVEILS NEW FAST-TRACK FRAMEWORK FOR PERSONALIZED GENE THERAPIES, ALLOWING COMPANIES TO MODIFY CERTAIN APPROVED TREATMENTS WITHOUT FILING ENTIRELY NEW DRUG APPLICATIONS — STAT NEWS
7
Ftavvv
$EDIT • Nov 8 (Sunday): Dr. Dan Ory drops the highly anticipated EDIT-401 preclinical durability data at the AHA Presentation. • Nov 9 (Monday): Q3 Earnings Release before the market opens. • Nov 10 (Tuesday): Management takes the stage at the Guggenheim Healthcare Conference for a live QA. First Human Patient Dosed" PR is Wednesday, November 11 (11.11). Think about it: 11.11 = Four 1s = EDIT-401 #EDIT #EditasMedicine #CRISPR #Biotech #PennyStocks #1111Catalyst
6
harryvanluik
$EDIT today marks the start of this "poster presentations at the European Society of Gene and Cell Therapy (ESGCT)". If anyone gets to see these presentations or at least the contents of the presentations then please tell us about it. TIA
1
3
0x126
$EDIT added twice. Old gods may help me. In this game for what, 10 years with edit? Biggest position is down 35% again. I hope they make revenue and approval early 27.
5
harryvanluik
$EDIT It is crazy bhow they are playing withnones money. On 15 june we were at 2,32 $ and 2 weeks later on 6 july Edit stood at 3,77...talking about a short-term gain:over 50%. With the news we may get after the weekend we may even fly higher.
5
Robert_Dempster
$EDIT thats right im still buying and im definitley not listening to short selling low lifes you cant get emotional about stocks cause when they come back, they come roaring back and that's what's gonna happen here you gotta make your own decisions 🐂
4
StockBraker
$EDIT DCAing at these levels. Never any guarantee on bio stocks - highest risk/reward. The good news is Editas reported in its Q3 2026 business update that its cash reserves are projected to fund operations into the second half of 2028, carrying the company past its key 2027 clinical readouts. Both 🤞🏻🤞🏻
4
Robert_Dempster
$EDIT if you're loading down here you're gonna be swinging for the fences soon great opportunity🐂
4
harryvanluik
$EDIT They are indeed trying everything to bring us down; but if your remember we were at $2,22 on 27 march this year and on 20 april we went over $ 3,59. These market makers are really earning a fortune on the back of some investors. You should however invest NOW and do the same as they did..earn big money in a couple of weeks.
4
ERadar
$EDIT after hours dip And reverse tells me smart money … AM Monday I expect the up on the V at open. Regardless we will fly very soon 🤙
3
StocktwitsEarnings
$EDIT Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.15 • Reported revenue of $10.37M • Editas Medicine expects existing cash, cash equivalents, and marketable securities to fund operating expenses and capital expenditure requirements into the second half of 2028, through and beyond key Strive study clinical readouts.
2
Robert_Dempster
$EDIT load load load🐂 their taking it down but soon it will bounce i know im not selling that complete idiot wham doesn't even know who owns the stock good luck bulls🍀
1
StockBraker
$EDIT Editas Medicine developed an experimental CRISPR gene-editing treatment for severe sickle cell disease called renizgamglogene autogedtemcel (reni-cel, formerly known as EDIT-301). Despite positive clinical results, Editas paused/shifted away from this ex vivo approach (which requires extracting cells and giving patients chemotherapy) to seek a partner for reni-cel while pivoting internal focus toward developing an in vivo (inside the body) gene editing treatment. Bluebird Bio was another company focused on SCD before being taken private. https://stocktwits.com/news-articles/markets/equity/novo-nordisk-seeks-fda-ema-approval-for-sickle-cell-disease-treatment-here-are-the-key-takeaways/cNbRT6aR9ff
1
Whoami1989
$EDIT this is very pathetically sick. the worst of all worse in the history of mainkind
1
EmilyLovesIt
$EDIT I don't usually enjoy unnecessary complications, but I can appreciate an opportunity with substance
Whoami1989
$EDIT the whole world is collapsing. this one just simply has 45% haircut. if i were you, i would find robert’s home address to ask for reimbursement
Whoami1989
$EDIT where is idiotic robert? you need to reimburse people’s loss due to your stupidity

Advertisement|Remove ads.